title: Ghrelin and bone mass in postmenopausal hypertensive women.
abstract: BACKGROUND
  Ghrelin, a recently discovered peptide mainly secreted by the stomach, has an orexigenic effect which stimulates secretion of the growth hormone. It also has vasodilator effects which reduce blood pressure and stimulate in vitro, bone formation.
  
  
  OBJECTIVE
  To evaluate the effect of ghrelin on bone mass and bone remodeling markers in postmenopausal hypertensive women.
  
  
  METHODS
  25 postmenopausal hypertensive women, light to moderate based on the JNC-VII criteria, were studied. They had a mean age of 58 +/- 8 years, a body mass index of 28 +/- 6 and a hypertension development time of 65 +/- 84 months. Osteocalcin, PTHi, 25-vitamin D, ghrelin in serum and deoxypiridinoline in urine were determined in all patients. A lumbar spine densitometer was made (DXP Lunar, Madison, Wisc., USA).
  
  
  RESULTS
  Diminished levels of ghrelin were observed in the osteoporotic group (40 +/- 19 vs. 78 +/- 40, p = 0.027). When the patients were separated according to ghrelin tertiles, a greater bone mass was observed in the upper tertiles, which was associated with a decrease in the urinary deoxypiridinoline. When the total population was analyzed, no relation between the ghrelin and bone mass was found, nor with any of the parameters of calcium metabolism. Only a statistically significant relation between ghrelin and deoxypiridinoline was observed (r = -0.428, p = 0.026).
  
  
  CONCLUSIONS
  In postmenopausal hypertensive women, ghrelin may produce a protecting effect over bone mass through an anticatabolic mechanism manifested by a decrease of bone resorption.
authors.affiliation: Department of Internal Medicine, Río Hortega University Hospital, Valladolid, Spain. castrv@terra.es <castrv@terra.es>
authors.forename: José L
authors.initials: JL
authors.lastname: Pérez-Castrillón
authors.forename: Isabel
authors.initials: I
authors.lastname: Justo
authors.forename: Alberto
authors.initials: A
authors.lastname: Sanz
authors.forename: Angel
authors.initials: A
authors.lastname: San Miguel
authors.forename: M Angeles
authors.initials: MA
authors.lastname: Mazón
authors.forename: Laura
authors.initials: L
authors.lastname: Abad
authors.forename: Gemma
authors.initials: G
authors.lastname: Vega
authors.forename: Antonio
authors.initials: A
authors.lastname: Dueñas
mesh_terms: D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density / Q000502:physiology*; D016723:Bone Remodeling / Q000502:physiology; D001862:Bone Resorption / Q000517:prevention & control; D002118:Calcium / Q000097:blood; D003720:Densitometry; D005260:Female; D054439:Ghrelin; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000503:physiopathology* / Q000652:urine; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000517:prevention & control; D010281:Parathyroid Hormone / Q000097:blood; D036361:Peptide Hormones / Q000097:blood*; D017698:Postmenopause; D014807:Vitamin D / Q000031:analogs & derivatives / Q000097:blood
chemical_list: D015415:Biomarkers; D054439:Ghrelin; D010281:Parathyroid Hormone; D036361:Peptide Hormones; D015675:Osteocalcin; D014807:Vitamin D; D002118:Calcium